A randomized, double-blind, placebo-controlled, 2-period crossover study to evaluate the effect of intranasal esketamine on cognitive functioning in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2018
Price : $35 *
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Pharmacodynamics
- Sponsors Janssen Research & Development
- 24 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Aug 2014 Planned End Date changed from 1 Jul 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record.
- 07 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.